MET and gastric cancer: Furthermore, various selective and non-selective c-MET tyrosine kinase inhibitors, including tinvatinib, AMG 337, and foretinib, have been evaluated in clinical trials for MET-positive GC, yet none have shown significant clinical benefit [115,116,117].